Prof. Yan Yu 于雁
Chief Physician, Professor
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for lung, esophageal, gastric, colorectal, liver, pancreatic, breast cancers, lymphoma, and myeloma. Expertise in chemotherapy, targeted therapy, immunotherapy, and integrative care. Manages metastases, effusions, pain, nausea, and anemia. Focuses on neoadjuvant/adjuvant regimens and personalized treatment for elderly patients.
Dr. Yan Yu is a Professor and Chief of the Sixth Internal Medicine Department at Harbin Medical University Cancer Hospital. A doctoral supervisor since graduating from Harbin Medical University in 1989, Dr. Yan completed postdoctoral research at the university and trained at UPMC Hillman Cancer Center in 2006. Research focuses on malignancy metastasis mechanisms, particularly in lung and gastrointestinal cancers.
Professional roles
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Member, Esophageal Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Chemotherapy Professional Committee, Heilongjiang Province
- Editorial Board Member, Tumor Research and Clinic
Name order: in Chinese the family name comes first (Yu Yan). Papers usually list the name as Yan Yu or Yu Y.
Selected publications
130 papers on PubMed matched by name and affiliation; 42 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochem Pharmacol, 2026 (senior author): FTO-mediated m(6)A demethylation of SNHG9 enhances PINK1-dependent mitophagy and reverses cisplatin resistance via nuclear EZH2 ubiquitination. PubMed 42600947
- Adv Sci (Weinh), 2026 (senior author): RBM10 Deficiency Promotes Anti-PD-1 Resistance in LUAD via STING Alternative Splicing-Driven CCL7 Signaling and Macrophage Polarization. PubMed 42325102
- Front Immunol, 2026 (senior author): The neuro-immune-vascular landscape of lung cancer brain metastasis: insights from organoid models. PubMed 42683414
- Front Immunol, 2026 (senior author): GlycoRNA in cancer immune regulation and progression: biological mechanisms and translational therapeutic prospects. PubMed 41890733
- Int J Cancer, 2026 (senior author): Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study. PubMed 40965980
- Histol Histopathol, 2025 (senior author): Expression pattern, immune signature, and prognostic value of RBM10 in human cancers. PubMed 39056107
- J Exp Clin Cancer Res, 2025 (senior author): RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma. PubMed 40069781
- Lung Cancer, 2024 (first author): Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison. PubMed 39549678
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion